Topical calcineurin inhibitors and lymphoma risk: Evidence update with implications for daily practice

American Journal of Clinical Dermatology

Volumn 14, Issue 3, 2013, Pages 163-178

  Siegfried, Elaine C ^a   Jaworski, Jennifer C ^b   Hebert, Adelaide A ^c  

^a SAINT LOUIS UNIVERSITY   (United States)

^b Prescott Medical Communications Group   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PIMECROLIMUS; TACROLIMUS;

CANCER RISK; CARCINOGENICITY; CLINICAL STUDY; DIAGNOSTIC ERROR; DISEASE SEVERITY; DRUG EXPOSURE; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GRAFT VERSUS HOST REACTION; HUMAN; LONG TERM CARE; LYMPHOMA; MAINTENANCE THERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT CARE; PATIENT SATISFACTION; POPULATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN CARCINOMA; SKIN INFECTION;

ADVERTISING AS TOPIC; ANIMALS; CALCINEURIN; DERMATITIS, ATOPIC; DRUG LABELING; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; RISK FACTORS; TACROLIMUS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84878756039     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0020-1     Document Type: Review

References (164)

1. Stuetz A, Baumann K, Grassberger M, et al. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol. 2006;141(3):199-212.
2. ® (tacrolimus) ointment 0.03% and ointment 0.1% [US prescribing information]. Deerfield: Fujisawa Healthcare, Inc. 2000.
3. ® (pimecrolimus) cream 1% [US prescribing information]. East Hanover: Novartis Pharmaceuticals Corporation. 2010.
4. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Protopic NDA 50-777 approval letter. December 8, 2000. http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2000/50777-Protopic-Approv.pdf. Accessed 23 Jan 2012.
5. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Elidel NDA 21-302 approval letter. December 13, 2001. http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2001/21-302-ELIDEL-Approv.pdf. Accessed 23 Jan 2012.
6. Data on file, Astellas Pharma US, 2012.
7. Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. J Drugs Dermatol. 2007;6(2):185-93.
8. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology. 2007;214(4):289-95.
9. Hanifin JM, Boguniewicz M, Eichenfield LF, et al. Long-term study of safety and allergic comorbidity development in a randomized trial of pimecrolimus cream in infants with atopic dermatitis [abstract]. J Invest Dermatol. 2010;130:S55 (Abstract 328).
10. Hanifin JM, Paller AS, Eichenfield LF, et al. The demographic profile of a large population of infants with atopic dermatitis: a longitudinal study on development of asthma and allergies [abstract]. J Am Acad Dermatol. 2007;56(Suppl 2):AB68 (Abstract P703).
11. Paller AS, Figliomeni ML, Hultsch T, et al. Efficacy and safety of pimecrolimus cream 1% in 1088 infants with atopic dermatitis: Results of the three year double-blind, vehicle controlled phase of the study of the atopic march [abstract]. Dermatitis. 2008;19(5):294-5.
12. Bishop M, Poulin Y, Qaqundah P, et al. A 5-year randomized study to investigate the safety of pimecrolimus cream 1% in the treatment of mild-to-moderate atopic dermatitis in infants: clinical safety [abstract]. J Am Acad Dermatol. 2011;64(2 Suppl 1):AB56 (Abstract P1301).
13. Poulin Y, Bishop M, Johnson A, et al. A 5-year randomized study to investigate the safety of pimecrolimus cream 1% in the treatment of mild-to-moderate atopic dermatitis in infants: immunological parameters [abstract]. J Am Acad Dermatol. 2011;64(2 Suppl 1):AB58 (Abstract P1310).
14. Briefing memorandum from Dianne Murphy, Director, Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration. February 15th, 2005 Pediatric Advisory Committee meeting on the possible risk of cancer from use of the topical immunosuppressants, February 7, 2005. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2-01-01- %20Briefing%20Memo.pdf. Accessed 23 Jan 2012.
15. US Food & Drug Administration (FDA). FDA approves updated labeling with boxed warning and medication guide for two eczema drugs, Elidel and Protopic [media release]. 2006 January 19 [online]. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm153941.htm. Accessed 18 Jan 2012.
16. ® (tacrolimus) ointment 0.03% and ointment 0.1% [US prescribing information]. Deerfield: Astellas Pharma US, Inc. 2011.
17. Minutes of the Pediatric Advisory Committee meeting. March 22, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/UCM208036.pdf. Accessed 23 Jan 2012.
18. Minutes of the Pediatric Advisory Committee meeting. May 16, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/UCM261384.pdf. Accessed 23 Jan 2012.
19. FDA cautions doctors on eczema treatment. Associated Press. USA Today. 2005 Mar 10.
20. Stein R. FDA considers warnings for eczema creams. Washington Post. 2005 Feb 12;Sect A: A.09.
21. Cancer warning over eczema creams. BBC News. 2005 Mar 11.
22. New warnings, risks, or restrictions for three skin drugs. ConsumerReports.org. 2005 Mar 15.
23. Elidel Lawsuits, Litigation & Lawyers - What you should know [online]. FreeAdvice Staff. http://injury-law.freeadvice.com/injury-law/drug- toxic-chemicals/elidel-lawsuit.htm. Accessed 8 Mar 2012.
24. Elidel and skin cancer [online]. LawyersandSettlements.com. http://www.lawyersandsettlements.com/case/elidel.html. Accessed 8 Mar 2012.
25. Elidel and the FDA 'black box' warning [online]. Awko Law. http://www.awkolaw.com/elidel/. Accessed 8 Mar 2012.
26. Eczema drugs Elidel and Protopic have been shown to cause cancer [online]. Weitz & Luxenberg P.C. http://www.weitzlux.com/eczema-elidel- protopic-cancer-218024.html. Accessed 8 Mar 2012.
27. Elidel law suit [online]. Oshman & Mirisola, LLP. http://www.oshmanlaw.com/pharmaceutical
28. Siegfried E, Silverman RA, Mancini AJ. 'Black box' warning ill-advised for eczema drugs. Dermatol Times. 2006;27(3):6.
29. Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006;54(5):818-23.
30. Lebwohl M, Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. MedGenMed. 2006;8(4):8.
31. Thaci D, Salgo R. The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update. Acta Dermatovenerol Alp Panonica Adriat. 2007;16(2):58, 60-62.
32. Orlow S. Calcineurin inhibitors and black boxes. Pediatric News. Mar 2006:24.
33. Fleischer AB Jr. Black box warning for topical calcineurin inhibitors and the death of common sense. Dermatol Online J. 2006;12(6):2.
34. Maddin S. Pimecrolimus and tacrolimus: the US FDA public health advisory. Skin Therapy Lett. 2005;10(4):1-3.
35. Canadian Dermatology Association (CDA). Position statement on topical calcineurin inhibitors [media release]. 2005 April [online]. http://www.dermatology.ca/media/position-statement/position-topical-calcineurin- inhibitors.html. Accessed 24 Jan 2012.
36. American Academy of Dermatology (AAD). American Academy of Dermatology issues statement in response to FDA decision related to two eczema medications [media release]. 2005 March 20 [online]. http://www.thefreelibrary.com/ American+Academy+of+Dermatology+Issues+Statement+In+Response+to+FDA-a0130070456. Accessed 5 Apr 2012.
37. Fleischer AB. Show me the signal, FDA. Skin Allergy News. May 2005:10.
38. Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep. 2006;6(4):270-4.
39. Lebwohl M. Labeling changes for the topical calcineurin inhibitors: an expert interview with Mark Lebwohl, MD. Medscape Dermatol. 2006;7(1).
40. Bieber T, Cork M, Ellis C, et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology. 2005;211(2):77-8.
41. Eichenfield L. Topical pimecrolimus, tacrolimus, and the risk for cancer: an expert interview with Lawrence Eichenfield, MD. Medscape Dermatol. 2005;6(1).
42. Fonacier L, Spergel J, Charlesworth EN, et al. Report of the topical calcineurin inhibitor task force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2005;115(6):1249-53.
43. Ceilley R, Eisenthal A. The unintended effects of a boxed warning. J Clin Aesthet Dermatol. 2009;2(9):33-9.
44. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Protopic NDA 50-777 pharmacology review. June 19, 2000. http://www.accessdata.fda.gov/drugsatfda- docs/nda/2000/50777-protopic.cfm. Accessed 19 Mar 2012.
45. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Elidel NDA 21-302 pharmacology review. November 6, 2001. http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2001/21-302-Elidel.cfm. Accessed 19 Mar 2012.
46. Pediatric Advisory Committee presentation from Barbara Hill, Division of Dermatologic and Dental Drug Products, FDA Center for Drug Evaluation and Research. Topical immunosuppressants (calcineurin inhibitors) - animal toxicology. February 15, 2005. http://www.fda.gov/ohrms/dockets/ac/05/slides/ 2005-4089s2-01-06-Hill.ppt. Accessed 2 Apr 2012.
47. ® (tacrolimus) capsules and injection [US prescribing information]. Deerfield: Astellas Pharma US, Inc. 2011.
48. ® (cyclosporine) soft gelatin capsules, oral solution, and injection [US prescribing information]. East Hanover: Novartis Pharmaceuticals Corporation. 2010.
49. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Elidel NDA 21-302 pharmacokinetics/toxicokinetics review. 2005. http://www.fda.gov/ohrms/dockets/ ac/05/briefing/2005-4089b2-01-07-Tox%20Review%20Redacted.pdf. Accessed 2 Apr 2012.
50. Minutes of the Pediatric Advisory Committee meeting. February 15, 2005. http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4089m1-Minutes.pdf. Accessed 4 Apr 2012.
51. Briefing document from Angelika Manthripragada, Epidemiologist, Division of Epidemiology, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Calcineurin inhibitor pediatric literature review, September 23, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255139.pdf. Accessed 23 Jan 2012.
52. Briefing document from Angelika Manthripragada, Epidemiologist, Division of Epidemiology, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Addendum: Update on calcineurin inhibitor pediatric literature review, May 10, 2011. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/ UCM255140.pdf. Accessed 23 Jan 2012.
53. Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol. 2011;165(3):465-73.
54. Hui RL, Lide W, Chan J, et al. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother. 2009;43(12):1956-63.
55. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4):808-16.
56. Schneeweiss S, Doherty M, Zhu S, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology. 2009;219(1):7-21.
57. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute [online]. http://seer.cancer.gov/faststats. Accessed 8 Jun 2012.
58. Carroll CL, Fleischer AB Jr. Tacrolimus: focusing on atopic dermatitis. Drugs Today (Barc). 2006;42(7):431-9.
59. Pediatric Advisory Committee presentation from Seth J Orlow, Chairman & Weinberg Professor of Pediatric Dermatology, Director, Center of Excellence in Cancers of the Skin, New York University School of Medicine. Melanocytic lesions in children and adolescents, March 22, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/UCM207878.pdf. Accessed 3 Apr 2012.
60. ® (tacrolimus) Ointment, February 15, 2005. http://www.fda.gov/ ohrms/dockets/ac/05/slides/2005-4089s2-03-01-Fujsawa%20FDA%20Feb%2015.ppt. Accessed 31 May 2012.
61. Ohtsuki M, Ohara H, Santos V, et al. Safety profiles of two large cohort studies of tacrolimus ointment for the treatment of atopic dermatitis: a prospective pediatric longitudinal evaluation study (APPLES) and japanese long-term safety study (J-LSS) [abstract]. In: Proceedings of the 22nd World Congress of Dermatology Meeting; 2011; Seoul, Korea, Poster P0327.
62. Briefing document from Namita Kothary, Safety Evaluator, Division of Pharmacovigilance I, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Update on Malignancies in Children, April 4, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/UCM255145.pdf. Accessed 23 Jan 2012.
63. Data on file, Valeant Pharmaceuticals North America LLC, 2012.
64. Briefing book from Fujisawa Healthcare, Inc. Discussion topic: risk evaluation, labeling, risk communication, and dissemination of information on potential cancer risk among pediatric patients treated for atopic dermatitis with topical dermatological immunosuppressants, January 27, 2005. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2-02-02- Protopic%20Fujisawa%20briefing.pdf. Accessed 6 Aug 2012.
65. ® ointment utilization trends following 2006 labeling changes, July 17, 2009. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/ UCM204723.pdf. Accessed 2 Apr 2012.
66. Gibbons RD, Amatya AK, Brown CH, et al. Post-approval drug safety surveillance. Annu Rev Public Health. 2010;31:419-37.
67. Arana A, Wentworth CE, Fernandez-Vidaurre C, et al. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the UK. Br J Dermatol. 2010;163(5):1036-43.
68. Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001;137(6):778-83.
69. Soderberg KC, Hagmar L, Schwartzbaum J, et al. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health. 2004;4:51.
70. Hagstromer L, Ye W, Nyren O, et al. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol. 2005;141(9):1123-7.
71. Zhang Y, Holford TR, Leaderer B, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control. 2004;15(4):419-28.
72. Miyagaki T, Sugaya M. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. J Dermatol Sci. 2011;64(1):1-6.
73. Krol A, Krafchik B. The differential diagnosis of atopic dermatitis in childhood. Dermatol Ther. 2006;19(2):73-82.
74. Elmer KB, George RM. Cutaneous T-cell lymphoma presenting as benign dermatoses. Am Fam Phys. 1999;59(10):2809-13.
75. National Eczema Association (NEA). Topical corticosteroids: Myths & facts [online]. http://www.nationaleczema.org/eczema-treatments/topical- corticosteroids Accessed 2 Apr 2012.
76. Aschoff R, Schmitt J, Knuschke P, et al. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011;20(10):832-6.
77. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2.
78. Zuberbier T, Brautigam M. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. J Eur Acad Dermatol Venereol. 2008;22(6):718-21.
79. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002;110(2):277-84.
80. Papp KA, Werfel T, Folster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol. 2005;52(2):240-6.
81. Mandelin JM, Rubins A, Remitz A, et al. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants: a two-year open-label study. Int J Dermatol. 2012;51(1):104-10.
82. Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol. 2005;53(2 Suppl 2):S186-94.
83. Langley RG, Eichenfield LF, Lucky AW, et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Pediatr Dermatol. 2008;25(3):301-7.
84. Remitz A, Harper J, Rustin M, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol. 2007;87(1):54-61.
85. Reitamo S, Rustin M, Harper J, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008;159(4):942-51.
86. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44(1 Suppl):S58-64.
87. Arellano FM, Arana A, Wentworth CE, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol. 2009;123(5):1111-6, 116 e1-13.
88. Arana A, Wentworth CW, Rivero E, et al. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCIs) [abstract]. Pharmacoepidemiol Drug Saf. 2010;19:S12 (Abstract 28).
89. Arana A, Wentworth CW, Rivero E, et al. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids and/or topical calcineurin inhibitors [abstract]. J Am Acad Dermatol. 2011;64(2 Suppl 1):AB3 (Abstract P203).
90. Guidance for Industry. Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products - content and format. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER). October 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm075096.pdf. Accessed 19 Mar 2012.
91. Beach JE, Faich GA, Bormel FG, et al. Black box warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J. 1998;53(3):403-11.
92. Advair Diskus 100/50, 250/50, and 500/50 (fluticasone propionate 100/250/500 mcg and salmeterol 50 mcg inhalation powder) [US prescribing information]. Research Triangle Park: GlaxoSmithKline. 2011.
93. Metronidazole tablets USP [US prescribing information]. Corona: Watson Pharma, Inc. 2010.
94. Metronidazole gel 0.75% USP [US prescribing information]. Hawthorne: Taro Pharmaceuticals USA, Inc. 2011.
95. US Food and Drug Administration (FDA). FDA modifies boxed warning for pulmonary arterial hypertension drug Letairis [media release]. 2011 March 4, [online]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2011/ ucm245848.htm. Accessed 21 June 2012.
96. Van Leent EJ, Ebelin ME, Burtin P, et al. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology. 2002;204(1):63-8.
97. Rubins A, Gutmane R, Valdmane N, et al. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol. 2005;125(1):68-71.
98. Ling M, Gottlieb A, Pariser D, et al. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. J Dermatolog Treat. 2005;16(3):142-8.
99. Van Leent EJ, De Vries HJ, Ebelin ME, et al. Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year. J Dermatolog Treat. 2007;18(1):19-22.
100. Undre NA, Moloney FJ, Ahmadi S, et al. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2009;160(3):665-9.
101. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol. 2001;144(4):781-7.
102. Lakhanpaul M, Davies T, Allen BR, et al. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%. Exp Dermatol. 2006;15(2):138-41.
103. Eichenfield LF, Ho V, Matsunaga J, et al. Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. J Dermatol. 2007;34(4):231-6.
104. Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis - a multicenter, 3-week, open-label study. Pediatr Dermatol. 2005;22(5):465-71.
105. Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child. 2003;88(11):969-73.
106. Reitamo S, Mandelin J, Rubins A, et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dermatol. 2009;48(4):348-55.
107. Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol. 2005;53(4):602-9.
108. Meingassner JG, Aschauer H, Stuetz A, et al. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol. 2005;14(10):752-7.
109. Billich A, Aschauer H, Aszodi A, et al. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269(1):29-35.
110. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg. 2001;20(4):233-41.
111. Schweitzer A, Figueiredo J, Zehender H, et al. Pimecrolimus (SDZ ASM 981) has higher affinity for the skin than tacrolimus (FK 506) - a tissue distribution study in rats [abstract]. J Eur Acad Dermatol Venereol. 2002;16(Suppl 1):257 (Abstract P24-27).
112. Grassberger M, Steinhoff M, Schneider D, et al. Pimecrolimus - an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004;13(12):721-30.
113. Meingassner JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol. 1997;137(4):568-76.
114. ®,SDZ ASM 981): highly effective in animal models of skin inflammation but low activity in models of immunosuppression [abstract]. J Eur Acad Dermatol Venereol. 2001;15(Suppl 2):214 (Abstract P20-25).
115. Meingassner J, Hiestand P, Bigout M, et al. SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin A and FK 506 [abstract]. J Invest Dermatol. 2001;117(2):532 (Abstract 858).
116. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Protopic NDA 50-777 medical review. June 19, 2000. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2000/ 50777-protopic.cfm. Accessed 23 Jan 2012.
117. ®), May 16, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/UCM261387.pdf. Accessed 3 Apr 2012.
118. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Elidel NDA 21-302 medical review. November 6, 2001. http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2001/21-302-Elidel.cfm. Accessed 5 Apr 2012.
119. Prodanovic E, Siegfried E, Peter J. Number and cost analysis of ed admissions for atopic dermatitis [abstract]. Caribbean Dermatology Symposium; 2010 Jan 19-23; San Juan, Puerto Rico.
120. AMA House of Delegates Health and Ethics Policies. Patient access to treatments prescribed by their physicians. H-120.988 2012. https://ssl3.ama- assn.org/apps/ecomm/PolicyFinderForm.pl?site=www.ama-assn.org&uri=/ama1/pub/ upload/mm/PolicyFinder/policyfiles/HnE/H-120.988.HTM. Accessed 23 Jan 2012.
121. Ingram JR, Martin JA, Finlay AY. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. Am J Clin Dermatol. 2009;10(4):229-37.
122. Schiffner R, Schiffner-Rohe J, Landthaler M, et al. Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids. Pharmacoeconomics. 2003;21(3):159-79.
123. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6 Suppl):S118-27.
124. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol. 2002;46(3):361-70.
125. Mancini AJ, Kaulback K, Chamlin SL. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol. 2008;25(1):1-6.
126. Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: who cares? Who pays? J Am Acad Dermatol. 1993;28(5 Pt 1):699-703.
127. Fivenson D, Arnold RJ, Kaniecki DJ, et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm. 2002;8(5):333-42.
128. Bisgaier J, Rhodes KV. Auditing access to specialty care for children with public insurance. N Engl J Med. 2011;364(24):2324-33.
129. Wang E, Lim BL, Than KY. Dermatological conditions presenting at an emergency department in Singapore. Singap Med J. 2009;50(9):881-4.
130. Siegfried E, Korman N, Molina C, et al. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis. J Dermatolog Treat. 2006;17(3):143-50.
131. Zuberbier T, Heinzerling L, Bieber T, et al. Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. Dermatology. 2007;215(4):325-30.
132. Sigurgeirsson B, Ho V, Ferrandiz C, et al. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(11):1290-301.
133. Gollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol. 2008;158(5):1083-93.
134. Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205(3):271-7.
135. Doss N, Kamoun MR, Dubertret L, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy Immunol. 2010;21(2 Pt 1):321-9.
136. Thaci D, Chambers C, Sidhu M, et al. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol. 2010;24(9):1040-6.
137. Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatolog Treat. 2010;21(1):34-44.
138. Breneman D, Fleischer AB Jr, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008;58(6):990-9.
139. Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008;159(6):1348-56.
140. Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63(6):742-50.
141. Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2009;123(5):1124-33.
142. Queille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis. 2000;42(6):349-50.
143. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111(3):396-8.
144. Kyllonen H, Remitz A, Mandelin JM, et al. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol. 2004;150(6):1174-81.
145. Lubbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7(2):121-31.
146. Freeman AK, Serle J, VanVeldhuisen P, et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis. 2004;73(4):267-71.
147. Kang S, Paller A, Soter N, et al. Safe treatment of head/neck AD with tacrolimus ointment. J Dermatolog Treat. 2003;14(2):86-94.
148. Doss N, Reitamo S, Dubertret L, et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. Br J Dermatol. 2009;161(2):427-34.
149. Nivenius E, van der Ploeg I, Jung K, et al. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Eye (Lond). 2007;21(7):968-75.
150. Kawakami T, Soma Y, Morita E, et al. Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Dermatology. 2001;203(1):32-7.
151. Hoeger PH, Lee KH, Jautova J, et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. Br J Dermatol. 2009;160(2):415-22.
152. Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol. 2007;157(5):954-9.
153. Leung DY, Hanifin JM, Pariser DM, et al. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. Br J Dermatol. 2009;161(2):435-43.
154. Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-15 (quiz 16-8).
155. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology. 2005;211(2):174-87.
156. Kalthoff FS, Chung J, Musser P, et al. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol. 2003;133(3):350-9.
157. Meingassner JG, Kowalsky E, Schwendinger H, et al. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol. 2003;149(4):853-7.
158. Kwiek B, Peng WM, Allam JP, et al. Tacrolimus and TGF-beta act synergistically on the generation of Langerhans cells. J Allergy Clin Immunol. 2008;122(1):126-32, 132 e1.
159. Meindl S, Vaculik C, Meingassner JG, et al. Differential effects of corticosteroids and pimecrolimus on the developing skin immune system in humans and mice. J Invest Dermatol. 2009;129(9):2184-92.
160. Schuller E, Oppel T, Bornhovd E, et al. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol. 2004;114(1):137-43.
161. Krummen MB, Varga G, Steinert M, et al. Effect of pimecrolimus vs. corticosteroids on murine bone marrow-derived dendritic cell differentiation, maturation and function. Exp Dermatol. 2006;15(1):43-50.
162. Hoetzenecker W, Ecker R, Kopp T, et al. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2005;115(6):1276-83.
163. Fleischer AB Jr, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol. 2002;47(4):562-70.
164. Langley RG, Luger TA, Cork MJ, et al. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology. 2007;215(Suppl 1):27-44.